We are interested in therapies and technologies in the fields of Cardiovascular (covering heart, vascular, hemostatic and acute organ disorders, specialty lung and kidney diseases), Oncology, Gynecology and Ophthalmology which contribute to our research and help to promote innovative therapeutic ideas leading into novel drugs.





We are interested in new targets and tools, small molecules, biologics, animal models and biomarkers pertaining to the fields of:

    • Atrial Fibrillation
    • Chronic Heart Failure
    • Peripheral Artery Disease
    • Cardioprotective mechanisms
    • Acute Respiratory Distress Syndrome (ARDS)
    • Disseminated Intravascular Coagulation (DIC)
    • Systemic Inflammatory Response Syndrome (SIRS) - Non-infectious
    • Acute Renal Failure on ICU
    • Acute Coronary Syndrome (ACS)
    • Stroke prevention in Atrial Fibrillation
    • Venous Thrombosis
    • Hemophilia A
    • Diabetic Kidney Disease
    • Hypertensive Nephropathy
    • Polycystic Kidney Disease
    • Chronic Allograft Nephropathy
    • Acute Kidney injury
    • Idiopathic Pulmonary Fibrosis
    • Interstitial Lung Diseases
    • Chronic Obstructive Pulmonary Disease (COPD) – Frequent Exacerbators
    • Chronic Cough
    • Pulmonary Hypertension





    We are interested in new targets and tools, small molecules, and biologicals (i.e. function-blocking-antibodies) with a clear first-in-class potential, plasmids and cell lines, in-vitro technologies for functional analyses and animal models pertaining to the fields of:


    Oncogenic Signaling

    • Approaches towards tumor signaling targeting the “undruggables” such as Myc, Ras, p53 etc.

    • Tumor cell selective induction of apoptosis or other forms of cell death

    • Transcription and chromatin modulators

    • Selective targeting of tumor-specific metabolic dependencies


    Antibody drug conjugates (ADCs)





    We are interested in particular in animal models, new targets and tools, small molecules, biologicals (i.e. function-blocking antibodies), plasmids and cell lines, in-vitro technologies for functional analyses pertaining to the fields of:


    Hyper-proliferative diseases

    • Uterine fibroids (dysfunctional bleeding)

    • Adenomyosis uteri (pain and inflammation)

    • Polycystic ovary syndrome (PCOS)





    Our interest in ophthalmology lies with back of the eye diseases. We are looking for drug delivery technologies that allow convenient administration agents to the back of the eye (e.g. topical, or extended release IVT implants) and imaging technologies to quantify photoreceptor density.


    • Genetic retinal degenerative diseases (e.g. Stargardt Disease / Retinitis pigmentosa)

    • Macular degeneration (e.g. dry/wet AMD, DME)

    • Diabetic retinopathy (e.g. NPDR/ PDR)

    • Others (e.g. vitreomacular adhesion)

    • Innovative drug delivery technologies

    • Opportunistic interest in selected front-of-the-eye diseases in clinical development (e.g. dry eye, glaucoma)

    Anything else in your pipeline?
    Check out what technologies we are looking for